---
title: "Who is buying CGM? JD HEALTH released this market insight report"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/218875946.md"
description: "On November 4th, JD HEALTH released a market insight report, indicating that CGM (Continuous Glucose Monitoring) products are gradually replacing traditional BGM (Blood Glucose Monitoring) devices in diabetes management. Abbott's FreeStyle Libre 2 glucose meter was exclusively launched on JD, providing accurate real-time glucose readings suitable for diabetic children aged 4 and above. The annual sales growth rate of the CGM market is expected to remain above 22% from 2021 to 2024, reaching 44% in 2024. JD HEALTH plans to collaborate with various parties to promote the adoption of CGM technology in China"
datetime: "2024-11-05T23:08:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/218875946.md)
  - [en](https://longbridge.com/en/news/218875946.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/218875946.md)
---

# Who is buying CGM? JD HEALTH released this market insight report

On November 4th, Abbott Laboratories' brand new CGM (Continuous Glucose Monitoring) product - the FreeStyle Libre 2 glucose meter was exclusively launched on JD.com. This glucose meter is the only device in China that has passed iCGM (integrated Continuous Glucose Monitoring) verification, and it has undergone extensive clinical validation, providing accurate readings in the hypoglycemic range, with real-time glucose readings precise to every minute. Additionally, it is the first CGM product in China suitable for diabetic children aged 4 and above, free from the allergenic substance IBOA (isobornyl acrylate), ensuring safe use.

With the rising global prevalence of diabetes, blood glucose management has become a significant challenge in healthcare. During the JD 11.11 shopping festival, JD HEALTH and research firm Ipsos jointly released the "2024 Continuous Glucose Monitoring CGM Market Insights" (hereinafter referred to as: Market Insights), indicating that in the field of diabetes management, CGM is gradually replacing traditional BGM (blood glucose meters).

Data from JD HEALTH shows that the CGM market is experiencing robust growth, with annual sales growth rates consistently above 22% from 2021 to 2024, and reaching 44% so far in 2024, far exceeding BGM. Consumers purchasing CGM are primarily concentrated in major cities such as Beijing, Shanghai, and Guangzhou. These consumers tend to purchase diabetes medications, low-sugar foods, and digital products alongside CGM, demonstrating a more comprehensive demand for health management.

As an industry-leading new medical health service enterprise, JD HEALTH has always focused on the application and development of emerging technologies, optimistic about the tremendous growth potential of CGM technology in China. A relevant person in charge at JD HEALTH stated that they have formulated an active development plan and will share resources and cooperate mutually with various partners, including device manufacturers, medical institutions, research institutions, and insurance companies, to jointly promote the popularization and application of CGM technology in China, helping to elevate the blood glucose management level for diabetes patients to new heights

### Related Stocks

- [ABT.US](https://longbridge.com/en/quote/ABT.US.md)
- [86618.HK](https://longbridge.com/en/quote/86618.HK.md)
- [06618.HK](https://longbridge.com/en/quote/06618.HK.md)

## Related News & Research

- [JD.com Starts 2026 with Revenue Growth and Stronger Retail Margins Despite Profit Decline](https://longbridge.com/en/news/286078055.md)
- [JD.com Announces First Quarter 2026 Results | JD Stock News](https://longbridge.com/en/news/286072462.md)
- [Grupo Bimbo Achieves Positive Nutrition Across 98% of Its Everyday Consumption Portfolio | BMBOY Stock News](https://longbridge.com/en/news/286280100.md)
- [NVision Expands from Quantum Sensing to Quantum Computing to Accelerate Discovery and Validation of New Therapies](https://longbridge.com/en/news/286239950.md)
- [Basecare Wins NMPA Class III Approval for Gems Embryo Culture Medium](https://longbridge.com/en/news/286258287.md)